Ilhamjaya Patellongi
Faculty of Medicine, Hasanuddin University Jl. Perintis Kemerdekaan Km.10, Makassar

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Correlation between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis (ox-LDL) in Centrally Obese Men Priscilla Dian Ari; Ellis Susanti; Ilhamjaya Patellongi
The Indonesian Biomedical Journal Vol 4, No 2 (2012)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v4i2.168

Abstract

BACKGROUND: Obesity is closely associated with atherosclerosis. Obesity and atherosclerosis are closely associated with inflammatory disease. Atherosclerosis constitutes a multifactorial disorder affecting the arterial wall, which is initiated by dyslipidemia and excerbated by inflammation. Plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and oxidized low density lipoprotein (ox-LDL) have been identified as risk factors for cardiovascular disease.  Lp-PLA2 is the sole enzyme responsible for the hydrolysis of oxidized phospholipids (oxPL) on LDL particles in atherosclerosis plaque. Plasma level of oxLDL is associated with inflammation and plays an important role in the development of atherosclerosis. The aim of this study was to assess the correlation between Lp-PLA2 and atherosclerosis (oxLDL) in centrally obese men.METHODS: This was a cross-sectional study involving 71 men with central obesity with waist circumference >90 cm, aged 30-60 years old. Lp-PLA2 measurement was done by sandwich enzyme immunoassay. oxLDL measurement was done by ELISA method. RESULTS: Results of this study showed that central obesity correlated positively with oxLDL (r=0.258; p=0.040) and Lp-PLA2 >422 ng/mL correlated positively with oxLDL (r=0.331; p=0.042).CONCLUSIONS: We conclude that there is a correlation of Lp-PLA2 with atherosclerosis (oxLDL) in men with central obesity.KEYWORDS: obesity, Lp-PLA2, oxLDL, atherosclerosis
Correlation between Inflammation and Fibrinolysis Impairment on Central Obesity: A Study for hsCRP, PAI-1, PAP and TAFI Winni Agustiani; Mansyur Arif; Ilhamjaya Patellongi
The Indonesian Biomedical Journal Vol 3, No 2 (2011)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v3i2.143

Abstract

BACKGROUND: Inflammation in the vascular wall plays an important role in the pathogenesis of atherosclerosis. Current studies have shown that increase of systemic inflammatory marker like the acute phase component C-reactive protein (CRP) are associated with an unfavorable progression of disease and an increased risk for acute cardiovascular events. Recently, a close association of Metabolic Syndrome (MetS) with hemostatic abnormalities has been reported. Among hemostatic abnormalities, an increase in plasminogen activator inhibitor (PAI)-1, a strong inhibitor of fibrinolysis, is considered a core feature of MetS. High PAI-1 concentrations may be associated with thrombus formation, also causing cardiovascular events. Therefore, we investigated the association between markers for chronic inflammation (CRP) and the markers of fibrinolytic impairment (PAI-1, PAP, TAFI) in subjects with central obesity.METHODS: This was a cross-sectional study in 80 male Indonesian subjects, aged 30-60 years old with central obesity, conducted from January to March 2008 in Bandung.RESULTS: The study results showed that there was a difference of PAI-1 levels between MetS and Non-MetS group. There were significant correlations between hsCRP and PAI-1 (r=0.252, p=0.024 ), hsCRP and PAP (r=0.253, p=0.024), and also between PAI-1 and PAP (r=-0.239, p=0.033 ) respectively. But, no correlation found between hsCRP and TAFI.CONCLUSIONS: There was correlation between inflammation and fibrinolysis impairment on central obesity. Concentrations oh hsCRP, PAI-1 and TAFI were significantly higher in MetS.KEYWORDS: inflammation, fibrinolysis impairment, hsCRP, PAI-1, PAP, TAFI